Form 4 for ARQT Arcutis Biotherapeutics, Inc.

Accepted 2025-03-26 00:00:00 ET · period of report 2025-03-24 · accession 0001787306-25-000050 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2025-03-26	2025-03-24+	ARQT	Watanabe Todd Franklin	See Remarks, Dir	S - Sale	$17.54	-3,671	927.4K	-0.4%	-$64.4K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-03-25	S	D	2,171	$17.56	925,243	D	—	—	(F1) The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 14, 2024, by the Reporting Person, with a plan end date of September 30, 2025. (F3) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $17.51 to $17.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
2	Common	Common Stock	2025-03-24	S	D	1,500	$17.52	927,414	D	—	—	(F1) The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 14, 2024, by the Reporting Person, with a plan end date of September 30, 2025. (F2) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $17.50 to $17.63, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.